AYALA PHARMACEUTICALS INC (AYLA)
US05465V1089 - Common Stock
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IAA, POSH, AYLA, AGFS
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting
REHOVOT, Israel and WILMINGTON, Del., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company...
Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting
Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid Tumors
Ayala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Entered into a definitive merger agreement with Advaxis Inc. – transaction expected to close by end of Q1 2023, subject to approval by Ayala’s shareholders...
Ayala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FORG, AYLA, SPNE, OFIX
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE...
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
Ayala Pharmaceuticals to Host Key Opinion Leader Webinar on Desmoid Tumors
Event will feature a review of data from part A of the Phase 2/3 RINGSIDE trial of AL102KOLs and management to present on Thursday, October 6th @ 8 AM ET...
Ayala Pharmaceuticals to Host Key Opinion Leader Webinar on Desmoid Tumors
Ayala Pharmaceuticals Announces Fast Track Designation Granted by US FDA for AL102 in Progressing Desmoid Tumors
REHOVOT, Israel and WILMINGTON, Del., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company...